Acrivon Therapeutics (ACRV) Assets (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Assets of $107.8 million for Q1 2026, down 38.85% year-over-year from $176.3 million in Q1 2025, and down 16.87% quarter-over-quarter from $129.7 million in Q4 2025.
Acrivon Therapeutics (ACRV) Assets (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Assets for 6 consecutive years, with $107.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets fell 38.85% year-over-year to $107.8 million; the TTM figure through Mar 2026 stood at $107.8 million (down 38.85% YoY), while the FY2025 annual figure was $129.7 million, down 34.02% from the prior year.
- Assets retreated to $107.8 million in Q1 2026 per ACRV's latest filing, from $129.7 million in the prior quarter.
- Across five years, Assets topped out at $230.6 million in Q2 2024 and bottomed at $87.7 million in Q3 2022.
- Historically, Assets has averaged $157.9 million across 5 years, with a median of $158.6 million in 2025.
- Annual changes were most pronounced in 2023 — Assets surged 72.26% — and 2026, when it tumbled 38.85%.
- Acrivon Therapeutics' Assets stood at $181.2 million in 2022, then declined by 23.71% to $138.3 million in 2023, then jumped by 42.18% to $196.6 million in 2024, then plunged by 34.02% to $129.7 million in 2025, then slipped by 16.87% to $107.8 million in 2026.
- Business Quant data shows ACRV's Assets at $107.8 million in Q1 2026, $129.7 million in Q4 2025, and $145.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | Acrivon Therapeutics | 92.26 Mn | 92.26 Mn | - | 99.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 99.09 Mn |
| Mar 31, 2026 | 107.83 Mn |
| Dec 31, 2025 | 129.72 Mn |
| Sep 30, 2025 | 145.30 Mn |
| Jun 30, 2025 | 158.58 Mn |
| Mar 31, 2025 | 176.35 Mn |
| Dec 31, 2024 | 196.59 Mn |
| Sep 30, 2024 | 214.68 Mn |
| Jun 30, 2024 | 230.59 Mn |
| Mar 31, 2024 | 120.52 Mn |
| Dec 31, 2023 | 138.27 Mn |
| Sep 30, 2023 | 151.09 Mn |
| Jun 30, 2023 | 160.05 Mn |
| Mar 31, 2023 | 170.20 Mn |
| Dec 31, 2022 | 181.23 Mn |
| Sep 30, 2022 | 87.71 Mn |
| Dec 31, 2021 | 106.59 Mn |